Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Filings indexed 498 across all filing types
Latest filing 2019-11-13 Regulatory Filings
Country IN India
Listing BSE.NS BROOKS

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2019-11-13 English
Outcome of Board Meeting
Regulatory Filings
2019-11-13 English
Press Release
Regulatory Filings
2019-11-06 English
Board Meeting — Financial Results
Regulatory Filings
2019-11-05 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter dated 1st October 2019 addressed to stock exchanges regarding the closure of the trading window for insiders due to upcoming unaudited financial results for the second quarter and half year ended 30th September 2019. It references regulatory compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The document does not contain any financial data or results itself, nor does it present a report. It is an announcement related to trading restrictions ahead of financial results. The document length is short (1716 characters) and it is clearly an announcement rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about trading window closure.
2019-10-03 English
Shareholders meeting
Regulatory Filings
2019-09-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.